Document Detail

Nitrendipine and atenolol in essential hypertension in young and middle-aged patients: effect on serum lipids and left ventricular mass.
MedLine Citation:
PMID:  1723446     Owner:  NLM     Status:  MEDLINE    
This study was designed to compare the antihypertensive efficacy of nitrendipine and atenolol in young and middle-aged patients with mild or moderate essential hypertension and to assess treatment effects on plasma lipids and potential changes in left ventricular mass (LVM). After 2 weeks off medication and a 4-week placebo phase, patients who met the inclusion criteria [sitting diastolic blood pressure (DBP) 95 to 114 mm Hg, age below 50 years] entered a 12-week dose-adjustment and maintenance period with nitrendipine or atenolol. Serum lipids were determined before and after therapy. At the same time, LVM was evaluated echocardiographically (M mode). Twenty-two patients completed the double-blind, randomized study. After 12 weeks on nitrendipine, the systolic blood pressure (SBP) and DBP were reduced (p less than 0.005 and p less than 0.001, respectively). No significant changes in heart rate were observed. There were no changes in the lipid profile, and LVM was reduced from 93.7 to 23.4 to 82.4 +/- 22.6 g/m2 of body surface (p less than 0.05). On atenolol the SBP and DBP were reduced (p less than 0.001 and p less than 0.001, respectively). The expected reduction in heart rate was significant (p less than 0.05). Total cholesterol and LDL cholesterol increased by 11% (p less than 0.05) and 12.3% (p less than 0.01), respectively. HDL cholesterol showed a small reduction. Tryglycerides increased by 22% (n.s.). LVM did not change. In conclusion, nitrendipine and atenolol showed comparable antihypertensive efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)
N C López; J L Corral; L A Rincón; M R Arreaza; J Giralt; G A Galué; Y E Barrios; I Arocha
Related Documents :
3964986 - Hyperuricemia as a risk factor of coronary heart disease: the framingham study.
7295196 - Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries. stat...
1288276 - Association of serum albumin with blood pressure in the normative aging study.
6746846 - Serum cholesterol, other risk factors, and cardiovascular disease in a japanese cohort.
10090826 - End-diastolic pressure-volume relationship in sepsis: relative contributions of complia...
678176 - A proposed pilocarpine therapeutic test.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18 Suppl 1     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991  
Date Detail:
Created Date:  1992-03-10     Completed Date:  1992-03-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S101-5     Citation Subset:  IM    
Unidad de Hipertensión Arterial, Hospital Central de Maracay, Venezuela.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atenolol / adverse effects,  therapeutic use*
Blood Pressure / drug effects,  physiology
Double-Blind Method
Heart Rate / drug effects,  physiology
Heart Ventricles / drug effects*
Hypertension / drug therapy*,  physiopathology
Lipids / blood*
Middle Aged
Nitrendipine / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Lipids; 29122-68-7/Atenolol; 39562-70-4/Nitrendipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Calcium antagonists and tissue protection.
Next Document:  Influence of therapy on silent ischemia and ventricular arrhythmias in hypertensive patients.